Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response claim about the existence of anaphylactic reactions and the label-supported timing/severity aligns closely with the provided FDA prescribing information (Warnings and Precautions 5.1/5.2, Adverse Reactions 6.2, and Patient Counseling 17).
Category Scores
Accurate Statements
Life-threatening and fatal anaphylaxis is reported with glatiramer acetate injection (Copaxone).
Supported by Warnings and Precautions (5.1) and Adverse Reactions (6.2).
Anaphylaxis can occur at any time following initiation, from as early as after the first dose up to years after initiation.
Supported by Warnings and Precautions (5.1).
Anaphylaxis occurred within an hour of injection in most of the reported cases.
Supported by Warnings and Precautions (5.1).
Patients/caregivers should seek immediate emergency medical care and treatment must be immediately discontinued if anaphylaxis occurs.
Supported by Warnings and Precautions (5.1) and Patient Counseling Information (17).
Symptoms of immediate post-injection reactions may overlap with anaphylaxis, and prompt identification is important to avoid delay in treatment.
Supported by Warnings and Precautions (5.2).
Unsupported Statements
The claim explicitly evaluated: “WARNING: ANAPHYLACTIC REACTIONS / existence and timing/severity of anaphylaxis risk.”
The label text includes anaphylactic reactions as a warning topic; however, the provided excerpt does not show that the term is presented exactly as a boxed warning header. Despite this, the substance of the claim (existence and timing/severity) is directly supported by Warnings and Precautions (5.1).
Contradictions
Important Omissions
Whether the evaluated content should be treated specifically as a boxed warning vs a non-boxed warning header (not shown in the provided excerpt).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response content that addresses anaphylaxis existence and timing/severity is consistent with the provided label and includes appropriate label-aligned emergency/discontinuation instructions; no contradictory or unsupported safety risk claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response refers to 'WARNING: ANAPHYLACTIC REACTIONS' as a header, but the excerpt does not confirm the exact header formatting as a boxed warning title.
Suggested Improvement
Avoid implying exact boxed-warning/header wording; instead, tie the claim explicitly to Warnings and Precautions (5.1/5.2) and Patient Counseling (17).